Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 4/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.44 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | PLA2G7 | Q13093 | 2/20 | 0.41 |
| ▸ | FLT1 | P17948 | 8/20 | 0.39 |
| ▸ | KDR | P35968 | 8/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.39 |
| ▸ | KIT | P10721 | 2/20 | 0.39 |
| ▸ | CIT | O14578 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | HLA-A | P04439 | 1/20 | 0.39 |
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7128318 | 0.88 | MET (0.42) | CYP11B1CYP11B2LMNACYP3A4MAPT | |
| SCHEMBL15702657 | 0.80 | CYP11B1 (0.43) | CYP11B1CYP11B2CYP17A1CYP19A1CYP3A4 | |
| SCHEMBL4830003 | 0.76 | CYP11B1 (0.42) | CYP11B1CYP11B2 | |
| SCHEMBL2201541 | 0.76 | FLT1 (0.64) | FLT1KDRPDGFRBKITCIT | |
| SCHEMBL22093967 | 0.74 | PDE4A (0.41) | LMNACYP3A4MAPTAPEX1MAPK1 | |
| SCHEMBL31308997 | 0.74 | PDE4A (0.41) | LMNACYP3A4MAPTAPEX1MAPK1 | |
| SCHEMBL6844790 | 0.74 | PDXK (0.50) | LMNACYP3A4MAPTAPEX1MAPK1 | |
| SCHEMBL7129816 | 0.74 | KDM4E (0.40) | LMNACYP3A4APEX1MAPK1 | |
| SCHEMBL4828189 | 0.73 | HTR1A (0.50) | CYP11B1CYP11B2 | |
| SCHEMBL4824943 | 0.73 | KCNH2 (0.43) | CYP11B1CYP11B2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1107964-B1 | ISOQUINOLINE DERIVATIVES WITH ANGIOGENESIS INHIBITING ACTIVITY | NOVARTIS AG (CH) | 2010-03-03 | — | — | EP | disclosed |
| EP-1603566-B1 | USE OF ISOQUINOLINE DERIVATIVES FOR TREATING CANCER AND MAP KINASE RELATED DISEASES | NOVARTIS AG (CH) | 2009-01-21 | — | — | EP | disclosed |
| CN-1758910-A | Use of isoquinoline derivatives for treating cancer and MAP kinase related diseases | NOVARTIS AG (CH) | 2006-04-12 | — | — | CN | disclosed |
| EP-1603566-A1 | USE OF ISOQUINOLINE DERIVATIVES FOR TREATING CANCER AND MAP KINASE RELATED DISEASES | Novartis AG (CH) | 2005-12-14 | — | — | EP | disclosed |
| WO-2004080464-A1 | USE OF ISOQUINOLINE DERIVATIVES FOR TREATING CANCER AND MAP KINASE RELATED DISEASES | NOVARTIS AG (CH) | 2004-09-23 | — | — | WO | disclosed |
| CN-1152031-C | Isoquinoline derivatives having angiogenesis inhibitory activity | ��˹��ŵ�� | 2004-06-02 | — | — | CN | disclosed |
| US-6608071-B2 | Angiogenesis inhibitors as antitumor agents | NOVARTIS AG (CH) | 2003-08-19 | — | — | US | disclosed |
| US-20020010181-A1 | Isoquinoline derivatives with angiogenesis inhibiting activity | NOVARTIS AG (CH) | 2002-01-24 | — | — | US | disclosed |
| CN-1319100-A | Isoquinoline derivatives having angiogenesis inhibitory activity | NOVARTIS AG (CH) | 2001-10-24 | — | — | CN | disclosed |
| EP-1107964-A1 | ISOQUINOLINE DERIVATIVES WITH ANGIOGENESIS INHIBITING ACTIVITY | Novartis AG (CH) | 2001-06-20 | — | — | EP | disclosed |
| WO-2000009495-A1 | ISOQUINOLINE DERIVATIVES WITH ANGIOGENESIS INHIBITING ACTIVITY | NOVARTIS AG (CH) | 2000-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010181-A1 | Isoquinoline derivatives with angiogenesis inhibiting activity | VEGFA, CCNY, PGF | CYP11B1 403/4885CYP11B2 228/4885CYP17A1 1526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.